Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced ...

GLP-1s could help curb substance abuse – including alcohol and opioids, new study finds - Increasingly popular GLP-1 drugs ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 9:50 AM ESTCompany ParticipantsMartin Hogan - Senior Director ...

The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study ...

This study investigates the economic and marketing impact of Taylor Swift’s high-profile relationship with NFL player Travis Kelce on Kansas City Chiefs jersey sales. Leveraging sales data, media ...

Bayer AG (BAYRY) announced an update on their ongoing clinical study. The CHINANEO trial is a Phase 2 Bayer study in China testing how well a combo of darolutamide and hormone therapy works before ...

A growing body of neuroimaging research is pinpointing exactly how psychedelic drugs hijack the brain’s visual system to produce vivid hallucinations, even when a person’s eyes are closed. Studies ...

This paper examines whether Chinese development finance is associated with faster progress toward Millennium Development Goal ...

Adjuvant therapy with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) in patients with resected RCC was associated with early reductions in patient-reported quality of life (QoL), according to ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.